S. E. Gray

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

R. Navari, Cindy K. Nagy, S. E. Gray, 2013, Supportive Care in Cancer.

Therapy for Mild to Moderate Asthma.

V. Press, A. Cifu, S. E. Gray, 2022, Journal of the American Medical Association (JAMA).

Over-the-Counter Availability of Rescue Inhalers for Asthma.

V. Press, S. E. Gray, 2022, JAMA.

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

R. Navari, A. C. Kerr, S. E. Gray, 2011, The journal of supportive oncology.

De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy.

M. Strek, S. Montner, W. Stock, 2017, Chest.

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

R. Navari, A. C. Kerr, S. E. Gray, 2010 .

Treatment of chemotherapy-induced breakthrough nauea and vomiting.

R. Navari, S. E. Gray, S. Gray, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.